Overexpression of centrosomal protein Nlp confers breast carcinoma resistance to paclitaxel

References

• Vincent T. DeVita J SHS(Ed): CANCER:Principles and Practice of Oncology (ed 7th). Philadelphia, PA 19106 USA: LIPPINCOTT WILLIAMS & WILKINS.
   Google Scholar
• Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000; 11:265 - 83; http://dx.doi.org/10.1016/S0928-0987(00)00114-7; PMID: 11033070
   PubMed Web of Science ®Google Scholar
• Hatanaka H, Abe Y, Naruke M, Asai S, Miyachi H, Kawakami T, et al. Modulation of multidrug resistance in a cancer cell line by anti-multidrug resistance-associated protein (MRP) ribozyme. Anticancer Res 2001; 21:879 - 85; PMID: 11396179
   PubMed Web of Science ®Google Scholar
• Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995; 30:445 - 600; http://dx.doi.org/10.3109/10409239509083491; PMID: 8770536
   PubMed Web of Science ®Google Scholar
• Dingemans AC, van Ark-otte AJ, Span S, Scagliotti GV, der Valk PV, Postmus PE, et al. Topoisomerase II alpha and other drug resistance markers in advanced non-small cell lung cancer. Lung Cancer 2001; 32:117 - 28; http://dx.doi.org/10.1016/S0169-5002(00)00224-5; PMID: 11325482
   PubMed Web of Science ®Google Scholar
• DiPaola RS, Aisner J. Overcoming bcl-2- and p53-mediated resistance in prostate cancer. Semin Oncol 1999; 26:112 - 6; PMID: 10190792
   PubMed Web of Science ®Google Scholar
• Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, Jacobs N, et al. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 2003; 22:90 - 7; http://dx.doi.org/10.1038/sj.onc.1206056; PMID: 12527911
   PubMed Web of Science ®Google Scholar
• Salisbury JL, Whitehead CM, Lingle WL, Barrett SL. Centrosomes and cancer. Biol Cell 1999; 91:451 - 60; http://dx.doi.org/10.1016/S0248-4900(99)80086-0; PMID: 10519005
   PubMed Web of Science ®Google Scholar
• Godinho SA, Kwon M, Pellman D. Centrosomes and cancer: how cancer cells divide with too many centrosomes. Cancer Metastasis Rev 2009; 28:85 - 98; http://dx.doi.org/10.1007/s10555-008-9163-6; PMID: 19156503
   PubMed Web of Science ®Google Scholar
• Lingle WL, Salisbury JL. The role of the centrosome in the development of malignant tumors. Curr Top Dev Biol 2000; 49:313 - 29; http://dx.doi.org/10.1016/S0070-2153(99)49015-5; PMID: 11005025
   PubMed Web of Science ®Google Scholar
• Kong Q. Cell brain abnormalities in cancer development. Med Hypotheses 2003; 61:120 - 5; http://dx.doi.org/10.1016/S0306-9877(03)00143-9; PMID: 12781654
   PubMed Web of Science ®Google Scholar
• Lingle WL, Barrett SL, Negron VC, D'Assoro AB, Boeneman K, Liu W, et al. Centrosome amplification drives chromosomal instability in breast tumor development. Proc Natl Acad Sci USA 2002; 99:1978 - 83; http://dx.doi.org/10.1073/pnas.032479999; PMID: 11830638
   PubMed Web of Science ®Google Scholar
• Liu L, Zou P, Zhang M, Tian L, Liu F. Effect of polo-like kinase 1 gene silence on cell cycle and drug resistance in K562/A02 cell. Chin Med J (Engl) 2006; 119:605 - 8; PMID: 16620704
   PubMed Web of Science ®Google Scholar
• Ro S, Yang LX. Centrosomes–their role in tumors and cancer therapy. Anticancer Res 2004; 24:3269 - 73; PMID: 15510622
   PubMed Web of Science ®Google Scholar
• Anand S, Penrhyn-Lowe S, Venkitaraman AR. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 2003; 3:51 - 62; http://dx.doi.org/10.1016/S1535-6108(02)00235-0; PMID: 12559175
   PubMed Web of Science ®Google Scholar
• Dutertre S, Prigent C. Aurora-A overexpression leads to override of the microtubule-kinetochore attachment checkpoint. Mol Interv 2003; 3:127 - 30; http://dx.doi.org/10.1124/mi.3.3.127; PMID: 14993419
   PubMedGoogle Scholar
• Cogswell JP, Brown CE, Bisi JE, Neill SD. Dominant-negative polo-like kinase 1 induces mitotic catastrophe independent of cdc25C function. Cell Growth Differ 2000; 11:615 - 23; PMID: 11149596
   PubMedGoogle Scholar
• Yang H, He L, Kruk P, Nicosia SV, Cheng JQ. Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells. Int J Cancer 2006; 119:2304 - 12; http://dx.doi.org/10.1002/ijc.22154; PMID: 16894566
   PubMed Web of Science ®Google Scholar
• Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004; 10:262 - 7; http://dx.doi.org/10.1038/nm1003; PMID: 14981513
   PubMed Web of Science ®Google Scholar
• Peterson D, Lee J, Lei XC, Forrest WF, Davis DP, Jackson PK, et al. A chemosensitization screen identifies TP53RK, a kinase that restrains apoptosis after mitotic stress. Cancer Res 2010; 70:6325 - 35; http://dx.doi.org/10.1158/0008-5472.CAN-10-0015; PMID: 20647325
   PubMed Web of Science ®Google Scholar
• Spänkuch B, Kurunci-Csacsko E, Kaufmann M, Strebhardt K. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs. Oncogene 2007; 26:5793 - 807; http://dx.doi.org/10.1038/sj.onc.1210355; PMID: 17369857
   PubMed Web of Science ®Google Scholar
• Payton M, Bush TL, Chung G, Ziegler B, Eden P, McElroy P, et al. Preclinical Evaluation of AMG 900, a Novel Potent and Highly Selective Pan-Aurora Kinase Inhibitor with Activity in Taxane-Resistant Tumor Cell Lines. Cancer Res 2010; 70:9846 - 54; http://dx.doi.org/10.1158/0008-5472.CAN-10-3001; PMID: 20935223
   PubMed Web of Science ®Google Scholar
• Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004; 96:1659 - 68; http://dx.doi.org/10.1093/jnci/djh312; PMID: 15547178
   PubMed Web of Science ®Google Scholar
• Husain A, He G, Venkatraman ES, Spriggs DR. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res 1998; 58:1120 - 3; PMID: 9515792
   PubMed Web of Science ®Google Scholar
• Zhou C, Smith JL, Liu J. Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1. Oncogene 2003; 22:2396 - 404; http://dx.doi.org/10.1038/sj.onc.1206319; PMID: 12717416
   PubMed Web of Science ®Google Scholar
• Chabalier C, Lamare C, Racca C, Privat M, Valette A, Larminat F. BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle 2006; 5:1001 - 7; http://dx.doi.org/10.4161/cc.5.9.2726; PMID: 16639080
   PubMed Web of Science ®Google Scholar
• Harkin DP, Bean JM, Miklos D, Song YH, Truong VB, Englert C, et al. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell 1999; 97:575 - 86; http://dx.doi.org/10.1016/S0092-8674(00)80769-2; PMID: 10367887
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhan Q. Cell cycle-dependent expression of centrosomal ninein-like protein in human cells is regulated by the anaphase-promoting complex. J Biol Chem 2007; 282:17712 - 9; http://dx.doi.org/10.1074/jbc.M701350200; PMID: 17403670
   PubMed Web of Science ®Google Scholar
• Yu L, Song Y, Zhang Q, Zhan Q. Ninein-like protein is overexpressed in head and neck squamous cell carcinoma and contributes to cancer growth and resistance to apoptosis. Oncol Rep 2009; 22:789 - 98; PMID: 19724857
   PubMed Web of Science ®Google Scholar
• Qu D, Qu H, Fu M, Zhao X, Liu R, Sui L, et al. Increased expression of Nlp, a potential oncogene in ovarian cancer, and its implication in carcinogenesis. Gynecol Oncol 2008; 110:230 - 6; http://dx.doi.org/10.1016/j.ygyno.2008.04.015; PMID: 18538832
   PubMed Web of Science ®Google Scholar
• Jin S, Gao H, Mazzacurati L, Wang Y, Fan W, Chen Q, et al. BRCA1 interaction of centrosomal protein Nlp is required for successful mitotic progression. J Biol Chem 2009; 284:22970 - 7; http://dx.doi.org/10.1074/jbc.M109.009134; PMID: 19509300
   PubMed Web of Science ®Google Scholar
• Shao S, Liu R, Wang Y, Song Y, Zuo L, Xue L, et al. Centrosomal Nlp is an oncogenic protein that is gene-amplified in human tumors and causes spontaneous tumorigenesis in transgenic mice. J Clin Invest 2010; 120:498 - 507; http://dx.doi.org/10.1172/JCI39447; PMID: 20093778
   PubMed Web of Science ®Google Scholar
• Chesler L, Goldenberg DD, Collins R, Grimmer M, Kim GE, Tihan T, et al. Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction. Neoplasia 2008; 10:1268 - 74; PMID: 18953436
   PubMed Web of Science ®Google Scholar
• Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, Johnston PG, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003; 63:6221 - 8; PMID: 14559807
   PubMed Web of Science ®Google Scholar
• Lentini L, Amato A, Schillaci T, Insalaco L, Di LA. Aurora-A transcriptional silencing and vincristine treatment show a synergistic effect in human tumor cells. Oncol Res 2008; 17:115 - 25; PMID: 18669163
   PubMed Web of Science ®Google Scholar
• Spänkuch B, Heim S, Kurunci-Csacsko E, Lindenau C, Yuan J, Kaufmann M, et al. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo. Cancer Res 2006; 66:5836 - 46; http://dx.doi.org/10.1158/0008-5472.CAN-06-0343; PMID: 16740723
   PubMed Web of Science ®Google Scholar
• Gomez LA, de Las Pozas A, Reiner T, Burnstein K, Perez-Stable C. Increased expression of cyclin B1 sensitizes prostate cancer cells to apoptosis induced by chemotherapy. Mol Cancer Ther 2007; 6:1534 - 43; http://dx.doi.org/10.1158/1535-7163.MCT-06-0727; PMID: 17513602
   PubMed Web of Science ®Google Scholar
• Song Y, Zhao C, Dong L, Fu M, Xue L, Huang Z, et al. Overexpression of cyclin B1 in human esophageal squamous cell carcinoma cells induces tumor cell invasive growth and metastasis. Carcinogenesis 2008; 29:307 - 15; http://dx.doi.org/10.1093/carcin/bgm269; PMID: 18048386
   PubMed Web of Science ®Google Scholar
• Horwitz SB. Taxol (paclitaxel): mechanisms of action. Ann Oncol 1994; 5:Suppl 6 S3 - 6; PMID: 7865431
   PubMed Web of Science ®Google Scholar
• Abal M, Andreu JM, Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets 2003; 3:193 - 203; http://dx.doi.org/10.2174/1568009033481967; PMID: 12769688
   PubMed Web of Science ®Google Scholar
• Wang Y, O'Brate A, Zhou W, Giannakakou P. Resistance to microtubule-stabilizing drugs involves two events: beta-tubulin mutation in one allele followed by loss of the second allele. Cell Cycle 2005; 4:1847 - 53; http://dx.doi.org/10.4161/cc.4.12.2264; PMID: 16294009
   PubMed Web of Science ®Google Scholar
• Sève P, Reiman T, Lai R, Hanson J, Santos C, Johnson L, et al. Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site. Cancer Chemother Pharmacol 2007; 60:27 - 34; http://dx.doi.org/10.1007/s00280-006-0343-1; PMID: 17021819
   PubMed Web of Science ®Google Scholar
• Wang Y, Cabral F.. Paclitaxel resistance in cells with reduced beta-tubulin. Biochim Biophys Acta 2005; 1744:245 - 55; http://dx.doi.org/10.1016/j.bbamcr.2004.12.003; PMID: 15950754
   PubMed Web of Science ®Google Scholar
• Ferlini C, Raspaglio G, Mozzetti S, Distefano M, Filippetti F, Martinelli E, et al. Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance. Mol Pharmacol 2003; 64:51 - 8; http://dx.doi.org/10.1124/mol.64.1.51; PMID: 12815160
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228 - 47; http://dx.doi.org/10.1016/j.ejca.2008.10.026; PMID: 19097774
   PubMed Web of Science ®Google Scholar